Markets
NVS

3 Dividend Stocks Better Than Pfizer, Inc.

Pfizer reported third-quarter earnings this week that were generally underwhelming. The drugmaker announced that its sales sagged 2.2% to $12.36 billion and its adjusted EPS fell similarly by 2% year over year in the quarter. Pfizer's performance does little to encourage dividend investors that the company will return to profit growth next year, so let's consider three other dividend-paying drugmakers that may be better positioned next year to boost their dividend payout.

Source: Novartis

Plenty of dividend-friendly upside

Amgen 's 1.7% forward dividend yield may appear uninspiring versus Pfizer's 3.6% yield, but investors may find that Amgen is far better positioned to grow its payout than Pfizer is. That's because Amgen's 33% payout rate is well below Pfizer's 62% rate. Additionally, while Pfizer's top and bottom line are struggling, Amgen's results are accelerating.

Amgen's sales grew 6% in the past year to $5.03 billion last quarter, leading to EPS of $2.30, up 19% from a year ago. Sales growth is being led by Prolia, Xgeva, Vectibex, and Kyprolis. Combined, those four drugs posted sales of $805 million last quarter, up 47% from a year ago.

Importantly, Amgen is getting increasingly more profitable thanks to a major restructuring that includes cutting its workforce by 20%. As a result, Amgen's SG&A fell 16% and its operating margin jumped 6.9% year over year in the quarter. Overall, Amgen is guiding investors to expect sales of $19.8 billion to $20 billion and EPS of between $8.45 and $8.55 this year. But it's Amgen's 2015 guidance that's particularly noteworthy. The company expects to realize even greater benefits from its restructuring next year and is forecasting sales of $20.8 billion-$21.3 billion and EPS of between $9.05 and $9.40. Since Amgen has more than $28 billion in cash on the books and a low payout ratio, there appear to be plenty of tailwinds for dividend increases going forward.

Source: Novo Nordisk.

Riding a big global wave

Diabetes powerhouse Novo Nordisk 's biggest benefit may be its market-leading position in one of the world's fastest-growing indications. The company's market share in diabetes is nearly 30%, and given that the number of people with diabetes may soar to as many as 552 million by 2030, up from 366 million in 2011,Novo may be perfectly positioned to increase its dividend for years to come.

Rising demand for its diabetes product line is already helping boost sales. While the company hasn't yet reported its third-quarter results, second-quarter sales grew 6.3% and EPS grew 9.5% year over year.

To make sure that growth continues, the company is investing heavily in diabetes treatment R&D, including an aggressive $3.7 billion program that the company hopes will someday result in the first tablet form of insulin.

With Novo's insulin sales growing 12% and its operating margin improving 90 basis points to 39.9% in the first half of this year, the company appears to have plenty of sales and earnings momentum. For the full year, Novo expects sales and earnings to increase 7%, to 10% and 10%, respectively. If the company can continue to deliver that kind of performance, then a combination of share-price appreciation and dividend increases should more than make up for the fact that its 1.3% forward yield trails Pfizer.

Pfizer has a slate of challenges it's navigating, including the loss of Lipitor exclusivity in 2011, the loss of Viagra exclusivity in Europe last year, and the patent expiration of Celebrex this year. There's no question that Pfizer's balance sheet is solid. Its $33 billion in cash and short-term investments provides plenty of firepower, even after considering its planned $11 billion share-repurchase program. Having said that, future revenue and profit growth is critical to the long-term dividend growth, and since these other three companies are expected to see earnings grow, rather than shrink, in the coming year, they may prove to be better buys.

Top dividend stocks for the next decade

The smartest investors know that dividend stocks simply crush their non-dividend-paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here .

The article 3 Dividend Stocks Better Than Pfizer, Inc. originally appeared on Fool.com.

Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd owns Gundalow Advisors, LLC. Gundalow's clients do not have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days . We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .

Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

NVS AMGN NVO PFE

Other Topics

Stocks

The Motley Fool

Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

Learn More